Blocking the MAPK pathway can reverse these effects in PTC without BRAF mutation, but not in BRAF-mutant thyroid cancer due to loss of SWI/SNF subunits, rendering them insensitive to its redifferentiation effects. This evidence concerns the gene SMARCA1 and thyroid gland carcinoma.